natgillin/translations-raw huggingface dataset:
Efficib съдържа две различни лекарства, наречени ситаглиптин и метформин. ситаглиптин принадлежи към клас лекарства, наречени DPP-4 инхибитори (дипептидил пептидаза-4 инхибитори) метформин принадлежи към клас лекарства, наречени бигванидини.
Efficib contains two different medicines called sitagliptin and metformin. sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) metformin belongs to a class of medicines called biguanides.
Efficib трябва да се приема с храна, за да се избегнат стомашните проблеми, причинени от метформин.
Efficib should be taken with food to avoid any stomach problems caused by metformin.
Efient 10 mg филмирани таблетки Efient 5 mg филмирани таблетки Прасугрел (Prasugrel)
Efient 10 mg film-coated tablets Efient 5 mg film-coated tablets Prasugrel
Efient 10 mg филмирани таблетки прасугрел
Efient 10 mg film-coated tablets prasugrel
Efient 10 mg филмирани таблетки.
Efient 10 mg film-coated tablets.
Efient 10 mg: Всяка таблетка съдържа 10 mg прасугрел (като хидрохлорид).
Efient 10 mg: Each tablet contains 10 mg of prasugrel (as hydrochloride).
Efient 10 mg: Таблетките са бежови на цвят и оформени като шестограм, с ”10 MG” вдлъбнато релефно означение върху едната страна и “4759” върху другата.
Efient 10 mg: The tablets are beige and double-arrow shaped, with ”10 MG” debossed on one side and “4759” on the other.
Efient 5 mg филмирани таблетки прасугрел
Efient 5 mg film-coated tablets prasugrel
Efient 5 mg филмирани таблетки.
Efient 5 mg film-coated tablets.
Efient 5 mg: Всяка таблетка съдържа 5 mg прасугрел (като хидрохлорид).
Efient 5 mg: Each tablet contains 5 mg of prasugrel (as hydrochloride).
Efient 5 mg: Таблетките са жълти на цвят и оформени като шестограм, с “5 MG” вдлъбнато релефно означение върху едната страна и “4760” върху другата.
Efient 5 mg: The tablets are yellow and double-arrow-shaped, with “5 MG” debossed on one side and “4760” on the other.
Efient не трябва да се употребява при деца и юноши под 18-годишна възраст.
Efient should not be used in children and adolescents below 18 years of age.
Efient съдържа лактоза.
Efient contains lactose.
Efient, който съдържа активното вещество прасугрел, принадлежи към група лекарства, наречени тромбоцитни антиагреганти.
Efient, which contains the active substance prasugrel, belongs to a group of medicines called anti- platelet agents.
Efient, прилаган в начална доза от 60 mg, последвана от „поддържащи“ дози от 10 mg, е сравнен с клопидогрел (друг инхибитор на тромбоцитната агрегация) в едно основно проучване, като двете лекарства са приемани в комбинация с аспирин.
In one main study Efient, given as a 60-mg starting dose followed by 10-mg ‘maintenance’ doses, was compared with clopidogrel (another inhibitor of platelet aggregation), both medicines taken in combination with aspirin.
EFS (медиана)
EFS (median)
Efter administrering av en dos av 8 mg/kg har kräkning före resa ofta rapporterats.
Incidents of pre-travel vomiting, usually within two hours post-dosing were commonly reported after administration of the 8 mg/kg dose.
Efter administrering av en intravenös dos på 600 mg ceftarolinfosamil var ceftarolins farmakokinetik liknande hos friska äldre försökspersoner (≥ 65 år), och hos friska yngre vuxna försökspersoner (18-45 år).
Following administration of a single 600 mg intravenous dose of ceftaroline fosamil, the pharmacokinetics of ceftaroline were similar between healthy elderly subjects (≥ 65 years of age), and healthy young adult subjects (18-45 years of age).
Efter administrering av en intravenös dos på 600 mg radiomärkt ceftarolinfosamil hos friska vuxna män återfanns cirka 88 % av radioaktiviteten i urin och 6 % i feces.
Following the administration of a single 600 mg intravenous dose of radiolabelled ceftaroline fosamil to healthy male adults, approximately 88% of radioactivity was recovered in urine and 6% in faeces.
Efter administrering av läkemedlet återslut flaskan med korken, tvätta doseringssprutan i varmt vatten och låt den självtorka.
After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.
Efter administrering under hela dräktigheten och laktationsperioden hos råtta observerades ingen effekt på ungarnas födelsevikt eller tillväxt, även om mindre förändringar i fostervikt och fördröjd förbening av interparietalbenet observerades när ceftarolinfosamil gavs under organogenesen (se avsnitt 5.3).
Following administration throughout pregnancy and lactation in the rat, there was no effect on pup birth weight or growth, although minor changes in foetal weight and delayed ossification of the interparietal bone were observed when ceftaroline fosamil was administered during organogenesis (see section 5.3).
Efter beredning innehåller 1 ml lösning 167,3 mg ceftazidim och 41,8 mg avibaktam (se avsnitt 6.6).
After reconstitution, 1 mL of solution contains 167.3 mg of ceftazidime and 41.8 mg of avibactam (see section 6.6).
Efter dosering ska sprutan tvättas med varmt vatten och torkas.
After dosing, the syringe should be washed with hot water and dried.
Efter en enkelt intravenøs dosis på 0,1 mg/kg til hunde, var den totale legemsclearance 0,017 l/t·kg, fordelingsvoluminet var 0,14 l/kg og den terminale halveringstid var 7,0 timer.
In dogs, after a single intravenous dose at 0.1 mg/kg, the total body clearance was 0.017 L/h·kg, the volume of distribution was 0.14 L/kg and the terminal half-life was 7.0 hours.
Efter en intravenös engångsdos på 1 mg/kg var den initiala plasmaconcentrationen 1040 ng/ml.
Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 1040 ng/ml.
Efter en intravenös engångsdos på 1 mg/kg var den initiala plasmakoncentrationen 363 ng/ml.
Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 363 ng/ml.
Efter intramuskulär injektion på svin är den genomsnittliga halveringstiden i plasma ungefär 2,5 timmar.
In pigs, after intramuscular administration the mean plasma elimination half-life is approximately 2.5 hours.
Efter intravenös injektion på häst elimineras meloxikam med en terminal halveringstid på 8,5 timmar.
In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours.
Efter oral administrering absorberas emtricitabin snabbt och i hög grad med en maximal plasmakoncentration 1-2 timmar efter intag.
Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose.
Efter oral administrering är halveringstiden för eliminering av emtricitabin cirka 10 timmar.
Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours.
Efter rekonstitution innehåller 1 ml av lösningen 30 mg av ceftarolinfosamil.
After reconstitution, 1 ml of the solution contains 30 mg of ceftaroline fosamil.
Efter spädning:
After dilution
Efter spädning:
After dilution:
Efter subkutan administrering är meloxikam fullständigt biotillgängligt och en maximal medelplasmakoncentration på 0,73 μg/ml uppnås ca 2,5 tim efter administrering hos hund respektive 1,1 μg/ml ca 1,5 tim efter administrering hos katt.
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 µg/ml in dogs and 1.1 μg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively.
Efter subkutan injektion elimineras meloxikam med en halveringstid på 26 timmar hos yngre nötkreatur och 17,5 timmar hos lakterande kor.
Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.
Efter subkutan singeldos om 0,5 mg meloxikam/kg till yngre nötkreatur respektive till lakterande kor, uppnåddes C värde på 2,1 μg/ml efter 7,7 timmar hos yngre nötkreatur och 2,7 μg/ml efter 4 timmar hos
After a single subcutaneous dose of 0.5 mg meloxicam/kg, Cmax values of 2.1 μg/ml and 2.7 μg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.
Efter tillförsel av den sista dosen sjönk plasmanivåerna av fluoxetin och norfluoxetin gradvis på ett log-linjärt sätt.
Following the last dose administration, fluoxetine and norfluoxetine plasma levels declined steadily in a log-linear fashion.
Efter tillförsel kunde fluoxetin snabbt påvisas i plasma med genomsnittliga Tmax-värden mellan 1,25 och 1,75 timmar på dag 1 och mellan 2,5 och 2,75 timmar på dag 21.
After administration, fluoxetine readily appeared in plasma with mean Tmax values ranging from 1.25 to 1.75 hours on day 1 and from 2.5 to 2.75 hours on day 21.
Efter två intramuskulära doser om 0,4 mg meloxikam/kg till svin uppnåddes ett Cmax värde på 1,1-1,5 μg/ml efter 1 timme.
Following single intramuscular doses of 0.4 mg meloxicam/kg, a Cmax value of 1.1 to 1.5 μg/ml was reached within 1 hour in pigs.
Efter upprepad subkutan administrering av 1 mg/kg kroppsvikt en gång om dagen under 5 dagar i följd var ackumulationen 146 %.
Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 146%.
Efter upprepad subkutan administrering av 1 mg/kg kroppsvikt en gång om dagen under 5 dagar i följd var ackumulationen 250 %.
Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 250%.
Efter upprepad, oral administrering 2 dagar i följd med en daglig dos av 8 mg/kg var ackumulationen 218 %.
Following repeated oral administration for two consecutive days at a daily dose of 8 mg/kg, accumulation was 218%.
Efter vaccination dannes der inden for 4 timer en diffus hævelse, der kan være varm eller smertefuld, på injektionsstedet..
After vaccination a diffusely swollen reaction, which may be warm or painful, develops at the injection site within 4 hours.
Efter öppnande av flaskan skall förpackningen förvaras vid högst 25°C. Flaskans innehåll skall förbrukas inom 45 dagar efter öppnandet.
After opening the bottle, do not store above 25ºC. The content of the bottle should be used up within 45 days of opening.
Eftersom ingen klinisk studie har utförts av interaktionen mellan avibaktam och probenecid rekommenderas inte samadministrering av avibaktam och probenecid.
Since a clinical interaction study of avibactam and probenecid has not been conducted, co-administration of avibactam with probenecid is not recommended.
Eftersom maropitant ackumuleras i kroppen under en behandlingsperiod på 14 dagar på grund av mättad metabolism bör man vid långtidsbehandling noggrant övervaka leverfunktionen och biverkningar.
As maropitant is accumulated in the body during a 14 day treatment period due to metabolic saturation, careful monitoring of liver function and any adverse events should be implemented during long term treatment.
Eftersom maropitant ackumuleras i kroppen under en behandlingsperiod på 14 dagar på grund av mättad metabolism bör man vid långtidsbehandling noggrant övervaka leverfunktionen och biverkningar.
As maropitant is accumulated in the body during a 14 day treatment period due to metabolic saturation, careful monitoring of liver function should be implemented during long term treatment.
EFV + IDV +
EFV + IDV + NRTIs
EFV + IDV + НИОТs
EFV + IDV + NRTIs
EFV + NFV + НИОТs
EFV + NFV + NRTIs
EFV + НИОТs
EFV + NRTIs
EFV+IDV
(11.8)
EFV+IDV
EFV + IDV
EFV+ZDV+
EFV +
EFV+ZDV+3TC
EFV +
EFV/TDF/FTC = ефавиренц 600 mg, тенофовир 300 mg, емтрицитабин 200 mg под форма на Atripla FDC.
EFV/TDF/FTC = efavirenz 600 mg, tenofovir 300 mg, emtricitabine 200 mg in the form of Atripla FDC.
EGFR T790M-мутационният статус трябва да се определи, използвайки валидиран тест метод (вж. точка 4.4).
EGFR T790M mutation status should be determined by using a validated test method (see section 4.4).
EGFR допринася за клетъчния растеж в нормалните епителни тъкани, включително кожата и космените фоликули и е експресиран върху различни туморни клетки.
EGFR promotes cell growth in normal epithelial tissues, including the skin and hair follicle, and is expressed on a variety of tumour cells.
EGFR е трансмембранен гликопротеин, който е част от подсемейство на тип I рецептора за тирозин кинази, включващи EGFR (HER1/c-ErbB-1), HER2, HER3 и HER4.
EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR (HER1/c-ErbB-1), HER2, HER3, and HER4.
EGFR мутация+ EGFR мутация- Непушачи
EGFR Mutation+
eGFR на изходното ниво (ml/min/1,73m2), медиана (min, max)
Baseline eGFR (mL/min/1.73m2), median (min, max)
eGFR на изходното ниво (ml/min/1.73 m2 ), медиана (min, max)
Baseline eGFR (mL/min/1.73 m2 ), median (min, max)
EGFR се експресира върху клетъчната повърхност на нормалните и раковите клетки.
EGFR is expressed on the cell surface of normal cells and cancer cells.
eGFR ≥60 до <90 ml/min/1,73 m²
eGFR ≥60 to <90 ml/min/1.73 m²
EGFR-мутационнен статус и клинична характеристика
EGFR mutation status and clinical characteristics
Ei ole teada, kas mikafungiin eritub inimese rinnapiima.
It is not known whether micafungin is excreted in human breast milk.
EID50-50% ембрио инфекциозна доза-вирусния титър, необходим за предизвикване на инфекция в 50% от инокулираните ембриони.
EID50: 50% embryo infective dose - the virus titre required to produce infection in 50% of the embryos inoculated.
EID50: 50% ембрио инфекциозна доза-вирусния титър, необходим за предизвикване на инфекция в 50% от инокулираните ембриони.
EID50: 50% embryo infective dose - the titre required to infect 50% of the embryos inoculated with the virus.
Eimeria acervulina, щам 003 - 332 – 450 спорулирани ооцисти
Eimeria acervulina, strain 003 - 332–450 sporulated oocysts
Eimeria acervulina, щам 003 332–450
Eimeria acervulina, strain 003 332–450
Eimeria brunetti, щам 034 - 213 – 288 спорулирани ооцисти
Eimeria brunetti, strain 034 - 213–288 sporulated oocysts
Eimeria brunetti, щам 034 ...........................................213 – 288*
Eimeria brunetti, strain 034........................................
Eimeria brunetti, щам 034 213–288
Eimeria brunetti, strain 034 213–288
Eimeria maxima, щам 013 - 196 – 265 спорулирани ооцисти
Eimeria maxima, strain 013 - 196–265 sporulated oocysts
Eimeria maxima, щам 013 196–265
Eimeria maxima, strain 013 196–265
Eimeria necatrix, щам 033 - 340 – 460 спорулирани ооцисти
Eimeria necatrix, strain 033 - 340–460 sporulated oocysts
Eimeria necatrix, щам 033 340–460
Eimeria necatrix, strain 033 340–460
Eimeria necatrix, щам 033...........................................340 – 460*
Eimeria necatrix, strain 033 .......................................
Eimeria necatrix, щам 033...........................................340 – 460*
Eimeria necatrix, strain 033 ........................................
Eimeria tenella, щам 004 - 276 – 374 спорулирани ооцисти
Eimeria tenella, strain 004 - 276–374 sporulated oocysts
Eimeria tenella, щам 004 276–374
Eimeria tenella, strain 004 276–374
Eimeria tenella, щам 004.............................................276 – 374*
Eimeria tenella, strain 004 .........................................
Einsteinweg 101
Paediatric population
Eisai AB
Eisai S.r.l.
Eisai B.V.
Eisai Ltd.
Eisai Europe Limited European Knowledge Centre Mosquito Way, Hatfield Hertfordshire
Eisai Europe Limited European Knowledge Centre Mosquito Way
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Обединено кралство имейл: EUmedinfo@eisai.net
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom e-mail: EUmedinfo@eisai.net
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Обединено кралство
Eisai Europe Limited, European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
Eisai Limited
Eisai Limited,
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN,
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN.
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertforrdshire, AL10 9SN,
Eisai Limited, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Ltd
Eisai Ltd.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN,
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN,
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN,
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd.
Eisai B.V.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN,
Eisai Ltd, European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Обединено кралство e-mail: EUmedinfo@eisai.net
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom. e-mail: EUmedinfo@eisai.net
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Обединено кралство.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, Обединено кралство.
Eisai Ltd., European Knowledge Centre, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Великобритания
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire AL10 9SN, UK.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Великобритания
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, Обединено кралство
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, Обединено кралство.
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts AL10 9SN, United Kingdom.
Eisai S.r.l.
Eisai AB
Ej använt läkemedel och avfall ska kasseras enligt gällande anvisningar.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Ej använt läkemedel och avfall ska kasseras enligt gällande anvisningar.
Any unused product or waste material should be disposed of in accordance with local requirements.
Ej använt läkemedel och avfall skall kasseras enligt gällande anvisningar
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Ej använt läkemedel och avfall skall kasseras enligt gällande anvisningar.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Ej använt läkemedel och avfall skall kasseras enligt gällande anvisningar.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Ej använt läkemedel och avfall: läs bipacksedeln.
Disposal: read package leaflet
Ej använt veterinärmedicinskt läkemedel eller avfall ska destrueras enligt gällande anvisningar.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Ej använt veterinärmedicinskt läkemedel eller avfall skall destrueras enligt gällande anvisningar.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Ej använt veterinärmedicinskt läkemedel eller avfall skall destrueras enligt gällande anvisningar.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Ej känsliga organismer
Non-susceptible organisms
Ej relevant
Not applicable.
Ej relevant
Packaging
Ej relevant.
NO ENTRY
Ej relevant.
Not applicable
Ej speciesrelaterade brytpunkter2
Non-species related breakpoints2
Ej tillåtet för användning till lakterande djur som producerar mjölk för humankonsumtion.
Not authorised for use in horses producing milk for human consumption.
Ej tillåtet för användning till lakterande djur som producerar mjölk för humankonsumtion.
Not authorised for use in lactating animals producing milk for human consumption.
EJlHMHHHpaHe
Elimination
Eklira Genuair 322 µg прах за инхалация Аклидиниум (аклидиниев бромид)
Eklira Genuair 322 mcg inhalation powder Aclidinium (aclidinium bromide)
Eklira Genuair 322 микрограма прах за инхалация Аклидиниум (аклидиниев бромид)
Eklira Genuair 322 micrograms inhalation powder Aclidinium (aclidinium bromide)
Eklira Genuair е бял или почти бял прах.
Eklira Genuair is a white or almost white powder.
Eklira Genuair е лекарство, което съдържа активното вещество аклидиниум бромид (aclidinium bromide).
Eklira Genuair is a medicine that contains the active substance aclidinium bromide.
Eklira Genuair е по-ефективен от плацебо за подобряване на функцията на белите дробове при пациенти с ХОББ.
Eklira Genuair was more effective than placebo at improving how well the lungs work in patients with COPD.
Eklira Genuair е показан за отваряне на дихателните пътища и облекчаване на симптомите при ХОББ – сериозно, хронично белодробно заболяване, характеризиращо се със затруднено дишане.
Eklira Genuair is indicated to help open the airways and relieve symptoms of COPD, a serious, long- term lung disease characterised by breathing difficulties.
Eklira Genuair е показан за поддържащо бронходилататорно лечение за облекчаване на симптоми при възрастни пациенти с хронична обструктивна белодробна болест (ХОББ).
Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Eklira Genuair е показан за поддържащо лечение на Вашата хронична обструктивна белодробна болест и не трябва да се използва за лечение на внезапен пристъп на задух или хрипове.
Eklira Genuair is indicated for maintenance treatment of your chronic obstructive pulmonary disease, it should not be used to treat a sudden attack of breathlessness or wheezing.
Eklira Genuair не трябва да се използва при астма; клинични изпитвания с аклидиниев бромид при астма не са провеждани.
Eklira Genuair should not be used in asthma; clinical trials of aclidinium bromide in asthma have not been conducted.
Eklira Genuair не трябва да се използва при деца и юноши на възраст под 18 години.
Eklira Genuair is not for use in children or adolescents below 18 years of age.
Eklira Genuair не трябва да се използва при хора, които са свръхчувствителни (алергични) към аклидиниум бромид, атропин, други свързани антихолинергични бронходилататорни лекарства или към някоя от останалите съставки.
Eklira Genuair must not be used in people who are hypersensitive (allergic) to aclidinium bromide, atropine, other related anticholinergic bronchodilator medicines, or any of the other ingredients.
Eklira Genuair с храна и напитки
Using Eklira Genuair with food and drink
Eklira Genuair се използва за облекчаване на симптомите на хронична обструктивна белодробна болест (ХОББ) при възрастни.
Eklira Genuair is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults.